Logo

Swiss Federal Institute of Technology Lab to Use VisEn's Fluorescence Probes

Aug 23, 2006
NEW YORK (GenomeWeb News) – VisEn Medical today said that the Swiss Federal Institute of Technology will use its portfolio of in vivo fluorescence probes and fluorescence molecular tomography imaging system in its molecular imaging programs.
 
VisEn said its technologies are designed to identify, characterize, and quantify a range of biological phenomena in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular disease, and bone disease.
 
The technology will be used in the lab of Markus Rudin, whom the company has appointed to its scientific advisory board.
 
Rudin is a professor of molecular imaging and functional pharmacology at the Swiss Federal Institute of Technology and the University of Zürich. He has been the head of imaging technologies at Novartis.

Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.